参考文献/References:
[1].Powell-Wiley TM,Poirier P,Burke LE,et al. Obesity and cardiovascular disease:a scientific statement from the American Heart Association[J]. Circulation,2021,143(21):e984-e1010.
[2].Afshin A,Forouzanfar H,Reitsma MB,et al. Health effects of overweight and obesity in 195 countries over 25 years[J]. N Engl J Med,2017,377(1):13-27.
[3].Carbone S,Canada JM,Billingsley HE,et al. Obesity paradox in cardiovascular disease:where do we stand?[J]. Vasc Health Risk Manag,2019,15:89-100.
[4].Lavie CJ,Kachur S,de Schutter A. Is there an obesity paradox in coronary heart disease in Asia?[J]. Coron Artery Dis,2017,28(4):273-274.
[5].Jenkins DA,Bowden J,Robinson HA,et al. Adiposity-mortality relationships in type 2 diabetes,coronary heart disease,and cancer subgroups in the UK Biobank,and their modification by smoking[J]. Diabetes Care,2018,41(9):1878-1886.
[6].Koliaki C,Liatis S,Kokkinos A. Obesity and cardiovascular disease:revisiting an old relationship[J]. Metabolism,2019,92:98-107.
[7].Kumari R,Kumar S,Kant R. An update on metabolic syndrome:metabolic risk markers and adipokines in the development of metabolic syndrome[J]. Diabetes Metab Syndr,2019,13(4):2409-2417.
[8].Rana MN,Neeland IJ. Adipose tissue inflammation and cardiovascular disease:an update[J]. Curr Diab Rep,2022,22(1):27-37.
[9].Kunz HE,Hart CR,Gries KJ,et al. Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity[J]. Am J Physiol Endocrinol Metab,2021,321(1):E105-E121.
[10].Engin A. Endothelial dysfunction in obesity[J]. Adv Exp Med Biol,2017,960:345-379.
[11].Taqueti VR,di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options:JACC state-of-the-art review[J]. J Am Coll Cardiol,2018,72(21):2625-2641.
[12].Virdis A,Colucci R,Bernardini N,et al. Microvascular endothelial dysfunction in human obesity:role of TNF-α[J]. J Clin Endocrinol Metab,2019,104(2):341-348.
[13].Bajaj NS,Osborne MT,Gupta A,et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients[J]. J Am Coll Cardiol,2018,72(7):707-717.
[14].Paratz ED,Wilkinson LE,MacIsaac AI. Outcomes of obese and morbidly obese patients undergoing percutaneous coronary intervention[J]. Heart Lung Circ,2018,27(7):785-791.
[15].Ando T,Aoi S,Ashraf S,et al. Transradial versus transfemoral percutaneous coronary intervention of left main disease:a systematic review and meta-analysis of observational studies [J]. Catheter Cardiovasc Interv,2019,94(2):264-273.
[16].Holroyd EW,Sirker A,Kwok CS,et al. The relationship of body mass index to percutaneous coronary intervention outcomes:does the obesity paradox exist in contemporary percutaneous coronary intervention cohorts? Insights from the British Cardiovascular Intervention Society registry[J]. JACC Cardiovasc Interv,2017,10(13):1283-1292.
[17].Terada T,Forhan M,Norris CM,et al. Differences in short- and long-term mortality associated with BMI following coronary revascularization [J]. J Am Heart Assoc,2017,6(4):e005335.
[18].Mei X,Hu S,Mi L,et al. B ody mass index and all-cause mortality in patients with percutaneous coronary intervention:a dose-response meta-analysis of obesity paradox [J]. Obes Rev,2021,22(2):e13107.
[19].Azhari Z,Ismail MD,Zuhdi ASM,et al. Association between body mass index and outcomes after percutaneous coronary intervention in multiethnic South East Asian population:a retrospective analysis of the Malaysian National Cardiovascular Disease Database-Percutaneous Coronary Intervention(NCVD-PCI) registry[J]. BMJ Open,2017,7(11):e017794.
[20].Wang H,Gao Z,Zhao X,et al. Association of body mass index with mortality in Chinese patients after percutaneous coronary intervention:a large single-center data [J]. Cardiovasc Ther,2017,35(4).DOI: 10.1111/1755-5922.12271.
[21].Faggioni M,Baber U,Afshar AE,et al. Effects of body mass index on clinical outcomes in female patients undergoing percutaneous coronary intervention with drug-eluting stents:results from a patient-level pooled analysis of randomized controlled trials[J]. JACC Cardio vasc Interv,2018,11(1):68-76.
[22].赵俊,赵岭,刘聪聪,等. 体质指数对高龄稳定性冠心病患者经皮冠状动脉介入治疗术后远期预后的影响分析[J]. 中国医学前沿杂志(电子版),2021,13(2):47-51.
[23].Ma WQ,Sun XJ,Wang Y,et al. Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft? A systematic review and network meta-analysis[J]. Obes Rev,2018,19(9):1236-1247.
[24].Elagizi A,Kachur S,Lavie CJ,et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases[J]. Prog Cardiovasc Dis,2018,61(2):142-150.
[25].Durrer Schutz D,Busetto L,Dicker D,et al. European practical and patient-centred guidelines for adult obesity management in primary care[J]. Obes Facts,2019,12(1):40-66.
[26].国务院新闻办公室. 中国居民营养与慢性病状况报告（2020年）[J]. 营养学报,2020,42(6):521.
[27].Lu Y,Liu S,Qiao Y,et al. Waist-to-height ratio,waist circumference,body mass index,waist divided by height0.5 and the risk of cardiometabolic multimorbidity: a national longitudinal cohort study [J]. Nutr Metab Cardiovasc Dis,2021,31(9):2644-2651.
[28].Liu PJ,Ma F,Lou HP,et al. Comparison of the ability to identify cardiometabolic risk factors between two new body indices and waist-to-height ratio among Chinese adults with normal BMI and waist circumference[J]. Public Health Nutr,2017,20(6):984-991.
[29].丁胜楷,黄海涛,章美华,等. 急性心肌梗死患者行PCI后1年的生存状况及相关因素分析[J]. 心脑血管病防治,2019,19(4):315-317.
[30].Shah RV,Anderson A,Ding J,et al. Pericardial,but not hepatic,fat by CT is associated with CV outcomes and structure:the multi-ethnic study of atherosclerosis[J]. JACC Cardiovasc Imaging,2017,10(9):1016-1027.
[31].Hruskova J,Maugeri A,Podrou?ková H,et al. Association of cardiovascular health with epicardial adipose tissue and intima media thickness:the Kardiovize study[J]. J Clin Med,2018,7(5):113.
[32].Al-Mallah MH,Sakr S,Al-Qunaibet A. Cardiorespiratory fitness and cardiovascular disease prevention:an update[J]. Curr Atheroscler Rep,2018,20(1):1.
[33].Lee DH,Keum N,Hu FB,et al. Predicted lean body mass,fat mass,and all cause and cause specific mortality in men:prospective US cohort study[J]. BMJ,2018,362:k2575.
[34].Medina-Inojosa JR,Somers VK,Thomas RJ,et al. Association between adiposity and lean mass with long-term cardiovascular events in patients with coronary artery disease:no paradox[J]. J Am Heart Assoc,2018,7(10):e007505.
[35].Mcauley PA,Keteyian SJ,Brawner CA,et al. Exercise capacity and the obesity paradox in heart failure:the FIT(Henry Ford Exercise Testing) project[J]. Mayo Clin Proc,2018,93(6):701-708.
[36].Kondamudi N,Mehta A,Thangada ND,et al. Physical activity and cardiorespiratory fitness:vital signs for cardiovascular risk assessment[J]. Curr Cardiol Rep,2021,23(11):172.
相似文献/References:
[1]王宏宇.肥胖相关的代谢综合征及其心脏和血管损伤[J].心血管病学进展,2016,(4):331.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.001]
WANG Hongyu.Obesity-Related Metabolic Syndrome and Its Heart and Vascular Damage[J].Advances in Cardiovascular Diseases,2016,(7):331.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.001]
[2]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(7):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[3]樊德慧 金娟 韩宇博 田苗 刘莉.利钠肽与代谢综合征的研究进展[J].心血管病学进展,2020,(10):1074.[doi:10.16806/j.cnki.issn.1004-3934.20.10.018]
FAN Dehui,JIN Juan,HAN Yubo,et al.Research Progress of Natriuretic Peptide and Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2020,(7):1074.[doi:10.16806/j.cnki.issn.1004-3934.20.10.018]
[4]贺彩红 荣晶晶 潘宏伟.定量血流分数在急性心肌梗死中的应用进展[J].心血管病学进展,2021,(4):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
HE Caihong,RONG Jingjing,PAN Hongwei.Progress in the Application of Quantitative Flow Ratio in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(7):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
[5]陈佳仑 李树仁.不同策略血栓抽吸对于急性ST段抬高心肌梗死患者的研究进展[J].心血管病学进展,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
CHEN Jialun,LI Shuren.Different Strategies of Thrombus Aspiration in Patients with Acute ST Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
[6]梁晨笛 秦纲.经皮冠状动脉介入诊疗中穿刺路径研究进展[J].心血管病学进展,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
LIANG Chendi,QIN Gang.Puncture Routes in Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(7):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[7]马兴鸿 汪蕾 方纬.核素心肌显像在冠状动脉慢性完全闭塞临床诊疗中的应用价值[J].心血管病学进展,2022,(4):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
MA Xinghong,WANG Lei,FANG Wei.Application Value of Radionuclide Myocardial Imaging In the Clinical Diagnosis And Treatment of Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2022,(7):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
[8]张爽 吴娜琼.腔内影像学在冠状动脉支架内再狭窄诊治应用中的研究进展[J].心血管病学进展,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
ZHANG Shuang,WU Na qiong.Application of Intravascular Imaging in Diagnosis and Treatment of Coronary In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(7):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
[9]管翔 王宇 张成糕 周健 张艺 李庆国.经皮心室辅助装置在复杂高危冠状动脉介入治疗中的应用进展[J].心血管病学进展,2022,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
GUAN Xiang,WANG Yu,ZHANG Chenggao,et al.Application Progress of Percutaneous Ventricular Assist Device in Complex High-Risk Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(7):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
[10]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(7):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]